# Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery

> **NCT00194779** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 50 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- Estrogen Receptor-positive Breast Cancer
- HER2-positive Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Progesterone Receptor-positive Breast Cancer
- Stage IA Breast Cancer
- Stage IB Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer

## Interventions

- **DRUG:** doxorubicin hydrochloride
- **DRUG:** cyclophosphamide
- **DRUG:** paclitaxel
- **BIOLOGICAL:** filgrastim
- **DRUG:** capecitabine
- **DRUG:** methotrexate
- **DRUG:** vinorelbine tartrate
- **PROCEDURE:** needle biopsy
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** immunohistochemistry staining method
- **BIOLOGICAL:** trastuzumab
- **DRUG:** tamoxifen citrate
- **DRUG:** letrozole
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00194779
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2010-06
- **Final completion:** 2011-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00194779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00194779, "Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00194779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*